Heavy Metals, Estrogenics Among Research Priorities For FDA's Cosmetics Office
This article was originally published in The Rose Sheet
Executive Summary
FDA’s Office of Cosmetics and Colors continues with surveys to detect the presence of controversial ingredients in cosmetics, including asbestos in talc-containing products. Office’s Deputy Director Patricia Hansen provides an overview at the Personal Care Products Council’s recent scientific summit.
You may also be interested in...
FDA: ‘No Convincing Evidence’ Hormones In Cosmetics Pose Health Risk
FDA says it continues to monitor the issue of estrogens and progesterone in cosmetic products; however, in a recently published study an agency scientist notes that to date, FDA has found “no convincing evidence” that cosmetics containing the substances pose health risks. Products surveyed largely were found to be labeled properly, belying concerns that consumers may be exposing themselves unwittingly.
Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012
“The Rose Sheet” offers an overview of the year in cosmetics, analyzing 2012’s biggest news and the publication’s most-read stories. Highlights include a proposal in Obama’s 2013 budget request to institute cosmetics user fees, the rash of late-year warning letters and regulatory developments in California.
Phytoestrogens That “Mimic” Estrogen Beneficial For Menopausal Skin
Phytoestrogens may be an answer for women looking to minimize skin drying and loss of elasticity often caused by menopause, said Alchimie Forever co-creator Barbara Polla. The plant-derived ingredients offer effects similar to estrogen, without the hormonal impact.